Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.

MiDOG Expands Scientific Advisory Board with the Appointment of Dr. Curtis Huttenhower, Dr. Micah Kohles, and Dr. Krista A. Keller Leaders in microbiome science, clinical practice, and exotic animal ...

Explore how smart automation enables precise, reproducible workflows in anaerobic microbiome research, improving accuracy and ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% ...

Countable Labs announces advanced RNA quantification module for Countable PCR to support translational, biopharma, and ...

Ed Sheeran has celebrated changes to the national curriculum in England that mean more students will be able to study ...

“These results are encouraging, highlighting TET2-mutated clonal hematopoiesis as a potential biomarker to select patients ...

The reforms, unveiled by Education Secretary Bridget Phillipson, follow recommendations from Professor Becky Francis’s ...

Researchers at UW’s School of Medicine and the Institute for Research in Biomedicine Barcelona may have found an additional explanation as to why men and smokers are more likely to develop bladder ...

How AI, robotics, and precision medicine are transforming cancer care—bridging hope, technology, and humanity in the ongoing ...

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...

QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The ...